`Filed: September 8, 2014
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`________________
`
`ROXANE LABORATORIES, INC. AND
`PAR PHARMACEUTICAL, INC.
`Petitioners,
`
`v.
`
`JAZZ PHARMACEUTICALS, INC.
`Patent Owner
`
`________________
`
`Case CBM2014-00175
`Patent 7,765,107
`________________
`
`MANDATORY NOTICES BY JAZZ PHARMACEUTICALS, INC.
`UNDER 35 U.S.C. §§ 321-329 AND 37 C.F.R. §§ 42.8, 42.300 ET. SEQ.
`
`
`
`
`
`
`
`Case CBM2014-00175
`Patent 7,765,107
`Patent Owner Mandatory Notices
`
`
`REAL PARTY-IN-INTEREST
`
`Pursuant to the requirements of 37 C.F.R. § 42.8(b)(1), the undersigned state
`
`that Jazz Pharmaceuticals, Inc. (“Jazz Pharmaceuticals”) is the real party-in-
`
`interest. Jazz Pharmaceuticals is a corporation organized and existing under the
`
`laws of the State of Delaware, having a principal place of business at 3180 Porter
`
`Drive, Palo Alto, California 94304. Jazz Pharmaceuticals owns by assignment the
`
`entire right, title, and interest in U.S. Patent No. 7,765,107 (the “’106 patent”) by
`
`virtue of an Assignment of rights from the inventors, Dayton Reardon, Patti Engle
`
`and Bob Gagne. The Assignment was recorded with the United States Patent and
`
`Trademark Office on December 22, 2010, at Reel 025604, Frame 0903.
`
`RELATED MATTERS
`
`Pursuant to 37 C.F.R. § 42.8(b)(2), the undersigned state that the ’107 patent
`
`is the subject of three, currently-pending litigations: Jazz Pharmaceuticals, Inc. v.
`
`Roxane Laboratories, Inc., 2:10-cv-6108 (D.N.J.); Jazz Pharmaceuticals, Inc. v.
`
`Amneal Pharmaceuticals, LLC and Par Pharmaceutical, Inc., 2:13-cv-391
`
`(consolidated) (D.N.J.); and Jazz Pharmaceuticals, Inc. v. Ranbaxy Laboratories
`
`Ltd., et al., 2:14-cv-4467 (D.N.J.). The litigation over the ’107 patent in Jazz
`
`Pharms., Inc. v. Roxane Labs., Inc., was stayed prior to the Petitioners filing the
`
`present CBM Petition.
`
`
`
`
`
`Case CBM2014-00175
`Patent 7,765,107
`Patent Owner Mandatory Notices
`
`
`Additionally, one or more of the Petitioners have filed petitions for covered
`
`business methods review on related patents: U.S. Patent No. 7,895,059
`
`(CBM2014-00149); U.S. Patent No. 8,457,988 (CBM2014-00150); U.S. Patent
`
`No. 7,668,730 (CBM2014-00151); U.S. Patent No. 8,859,182 (CBM2014-00153);
`
`and U.S. Patent No. 7,765,106 (CBM2014-00161).
`
`Further, the following pending U.S. Patent applications claim the benefit of
`
`U.S. Patent Application No. 10/322,348, which the ’107 patent also claims the
`
`benefit of: U.S. Patent Application No. 14/196,603, filed on March 4, 2014, U.S.
`
`Patent Application No. 14/219,904, filed on March 19, 2014, and U.S. Patent
`
`Application No. 14/219,941 filed on March 19, 2014.
`
`LEAD COUNSEL AND BACK-UP COUNSEL (37 C.F.R. § 42.8(b)(3))
`
`Lead Counsel:
`
`
`
`F. Dominic Cerrito (Reg. No. 38,100)
`
`Contact Information:
`
`Quinn Emanuel Urquhart & Sullivan, LLP
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`51 Madison Avenue, 22nd Floor
`
`New York, NY 10010
`
`Email: nickcerrito@quinnemanuel.com
`
`Telephone: 212-849-7000
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Case CBM2014-00175
`Patent 7,765,107
`Patent Owner Mandatory Notices
`
`
`Back-Up Counsel:
`
`John V. Biernacki (Reg. No. 40,511)
`
`Contact Information:
`
`Jones Day
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`North Point
`
`901 Lakeside Avenue
`
`Cleveland, OH 44114
`
`Email: jvbiernacki@jonesday.com
`
`Telephone: 216-586-3939
`
`SERVICE INFORMATION
`
`Pursuant to 37 C.F.R. § 42.8(b)(4), please direct all correspondence to lead
`
`and back-up counsel at the above addresses. Patent Owner consents to email
`
`service at the above-specified email addresses.
`
`
`
`Date: September 8, 2014
`
`
`
`
`Respectfully submitted,
`
`By: /F. Dominic Cerrito (Reg. No. 38,100)/
` F. Dominic Cerrito
` Reg. No. 38,100
`QUINN EMANUEL URQUHART &
`SULLIVAN, LLP
`51 Madison Avenue, 22nd Floor
`New York, NY 10010
`General Tel: (212) 849-7000
`Direct Tel: (212) 849-7450
`Fax: (212) 849-7100
`nickcerrito@quinnemanuel.com
`
`
`
`Case CBM2014-00175
`Patent 7,765,107
`Patent Owner Mandatory Notices
`
`
`
`John V. Biernacki
`Reg. No. 40,511
`JONES DAY
`North Point
`901 Lakeside Avenue
`Cleveland, Ohio 44114
`General Tel: (216) 586-3939
`Direct Tel: (216) 586-7747
`Fax: (216) 579-0212
`jvbiernacki@jonesday.com
`
`Attorneys for Jazz Pharmaceuticals, Inc.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`________________
`
`ROXANE LABORATORIES, INC. AND
`PAR PHARMACEUTICAL, INC.
`Petitioners,
`
`v.
`
`JAZZ PHARMACEUTICALS, INC.
`Patent Owner
`
`________________
`
`Case CBM2014-00175
`Patent 7,765,107
`________________
`
`CERTIFICATE OF SERVICE
`
`
`
`
`
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6(e), the undersigned hereby certify that
`
`MANDATORY NOTICES BY JAZZ PHARMACEUTICALS, INC. and the
`
`attached POWER OF ATTORNEY and 3.73(b) STATEMENT were served on
`
`September 8, 2014 by filing these documents through the Patent Review
`
`Processing System, as well as e-mailing copies to aclement@lockelord.com and
`
`pfill@lockelord.com.
`
`Date: September 8, 2014
`
`
`
`
`
` Respectfully submitted,
`
`By: /F. Dominic Cerrito (Reg. No. 38,100)/
` F. Dominic Cerrito
` Reg. No. 38,100
`QUINN EMANUEL URQUHART &
`SULLIVAN, LLP
`51 Madison Avenue, 22nd Floor
`New York, NY 10010
`General Tel: (212) 849-7000
`Direct Tel: (212) 849-7450
`Fax: (212) 849-7100
`nickcerrito@quinnemanuel.com
`
`John V. Biernacki
`Reg. No. 40,511
`JONES DAY
`North Point
`901 Lakeside Avenue
`Cleveland, Ohio 44114
`General Tel: (216) 586-3939
`Direct Tel: (216) 586-7747
`Fax: (216) 579-0212
`jvbiernacki@jonesday.com
`Attorneys for Jazz Pharmaceuticals, Inc.
`
`